ALK and lung adenocarcinoma: The tyrosine kinase inhibitors (TKIs) of EGFR and ALK have been proven remarkably beneficial in bringing a better clinical outcome in patients with lung adenocarcinoma in both adjuvant or salvage settings (21, 22), whose impact upon the observation of PORT efficacy was not considered by these RCTs.